Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
1975 1
1977 2
1979 1
1980 1
1983 3
1984 2
1985 1
1986 1
1987 1
1988 2
1989 1
1990 1
1991 4
1992 2
1993 2
1994 2
1995 3
1996 4
1997 1
1998 4
1999 3
2000 7
2001 3
2002 4
2003 7
2004 2
2005 3
2006 8
2007 4
2008 6
2009 6
2010 10
2011 9
2012 16
2013 25
2014 23
2015 19
2016 17
2017 26
2018 16
2019 23
2020 26
2021 27
2022 16
2023 7
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

313 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Metastatic Digestive System Neuroendocrine Neoplasm"
Page 1
Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients.
Baruch EN, Youngster I, Ben-Betzalel G, Ortenberg R, Lahat A, Katz L, Adler K, Dick-Necula D, Raskin S, Bloch N, Rotin D, Anafi L, Avivi C, Melnichenko J, Steinberg-Silman Y, Mamtani R, Harati H, Asher N, Shapira-Frommer R, Brosh-Nissimov T, Eshet Y, Ben-Simon S, Ziv O, Khan MAW, Amit M, Ajami NJ, Barshack I, Schachter J, Wargo JA, Koren O, Markel G, Boursi B. Baruch EN, et al. Science. 2021 Feb 5;371(6529):602-609. doi: 10.1126/science.abb5920. Epub 2020 Dec 10. Science. 2021. PMID: 33303685 Clinical Trial.
The gut microbiome has been shown to influence the response of tumors to anti-PD-1 (programmed cell death-1) immunotherapy in preclinical mouse models and observational patient cohorts. ...In this study, we performed a phase 1 clinical trial to assess the safety and …
The gut microbiome has been shown to influence the response of tumors to anti-PD-1 (programmed cell death-1) immunotherapy in preclin …
Management of immune-related adverse events and kinetics of response with ipilimumab.
Weber JS, Kähler KC, Hauschild A. Weber JS, et al. J Clin Oncol. 2012 Jul 20;30(21):2691-7. doi: 10.1200/JCO.2012.41.6750. Epub 2012 May 21. J Clin Oncol. 2012. PMID: 22614989 Review.
Monoclonal antibodies directed against the immune checkpoint protein cytotoxic T-lymphocyte antigen-4 (CTLA-4; CD152)-ipilimumab and tremelimumab-have been investigated in metastatic melanoma and other cancers and have shown promising results. Recently, ipilimumab was appr …
Monoclonal antibodies directed against the immune checkpoint protein cytotoxic T-lymphocyte antigen-4 (CTLA-4; CD152)-ipilimumab and tremeli …
(177)Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial.
Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, Mittra E, Wolin EM, Yao JC, Pavel ME, Grande E, Van Cutsem E, Seregni E, Duarte H, Gericke G, Bartalotta A, Mariani MF, Demange A, Mutevelic S, Krenning EP; NETTER-1 investigators. Strosberg JR, et al. Lancet Oncol. 2021 Dec;22(12):1752-1763. doi: 10.1016/S1470-2045(21)00572-6. Epub 2021 Nov 15. Lancet Oncol. 2021. PMID: 34793718 Clinical Trial.
Patients were 18 years and older with locally advanced or metastatic, well differentiated, somatostatin receptor-positive midgut neuroendocrine tumours (Karnofsky performance status score 60) and disease progression on fixed-dose long-acting octreotide. ...Th …
Patients were 18 years and older with locally advanced or metastatic, well differentiated, somatostatin receptor-positive midgut n …
Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab.
Chaput N, Lepage P, Coutzac C, Soularue E, Le Roux K, Monot C, Boselli L, Routier E, Cassard L, Collins M, Vaysse T, Marthey L, Eggermont A, Asvatourian V, Lanoy E, Mateus C, Robert C, Carbonnel F. Chaput N, et al. Ann Oncol. 2017 Jun 1;28(6):1368-1379. doi: 10.1093/annonc/mdx108. Ann Oncol. 2017. PMID: 28368458 Free article.
BACKGROUND: Ipilimumab, an immune checkpoint inhibitor targeting CTLA-4, prolongs survival in a subset of patients with metastatic melanoma (MM) but can induce immune-related adverse events, including enterocolitis. We hypothesized that baseline gut microbiota could pre …
BACKGROUND: Ipilimumab, an immune checkpoint inhibitor targeting CTLA-4, prolongs survival in a subset of patients with metastatic me …
Autoimmune gastritis: Pathologist's viewpoint.
Coati I, Fassan M, Farinati F, Graham DY, Genta RM, Rugge M. Coati I, et al. World J Gastroenterol. 2015 Nov 14;21(42):12179-89. doi: 10.3748/wjg.v21.i42.12179. World J Gastroenterol. 2015. PMID: 26576102 Free PMC article. Review.
In advanced cases, the oxyntic epithelia are replaced by atrophic (and metaplastic) mucosa, creating the phenotypic background in which both gastric neuroendocrine tumors and (intestinal-type) adenocarcinomas may develop. Despite improvements in our understanding of …
In advanced cases, the oxyntic epithelia are replaced by atrophic (and metaplastic) mucosa, creating the phenotypic background in which both …
Endoscopic and Surgical Management of Non-Metastatic Ampullary Neuroendocrine Neoplasia: A Multi-Institutional Pancreas2000/EPC Study.
Karam E, Hollenbach M, Abou Ali E, Auriemma F, Anderloni A, Barbier L, Belfiori G, Caillol F, Crippa S, Del Chiaro M, De Ponthaud C, Dahel Y, Falconi M, Giovannini M, Heling D, Inoue Y, Jarnagin WR, Leung G, Lupinacci RM, Mariani A, Masaryk V, Miksch RC, Musquer N, Napoleon B, Oba A, Partelli S, Petrone MC, Prat F, Repici A, Sauvanet A, Salzmann K, Schattner MA, Schulick R, Schwarz L, Soares K, Souche FR, Truant S, Vaillant JC, Wang T, Wedi E, Werner J, Weismüller TJ, Wichmann D, Will U, Zaccari P, Gulla A, Heise C, Regner S, Gaujoux S; Pancreas 2000 Research Group. Karam E, et al. Neuroendocrinology. 2023;113(10):1024-1034. doi: 10.1159/000531712. Epub 2023 Jun 27. Neuroendocrinology. 2023. PMID: 37369186
INTRODUCTION: Ampullary neuroendocrine neoplasia (NEN) is rare and evidence regarding their management is scarce. ...The pN1/2 rate was 51.9% (n = 14) after PD. Tumor size larger than 1 cm (i.e., pT stage >1) was a predictor for R1 resection (p < 0.001 …
INTRODUCTION: Ampullary neuroendocrine neoplasia (NEN) is rare and evidence regarding their management is scarce. ...The pN1/2 rate w …
Metastatic Neoplasms Involving the Stomach.
Vyas M, Hissong E, Gonzalez RS, Shia J, Jessurun J. Vyas M, et al. Am J Clin Pathol. 2022 Jun 7;157(6):863-873. doi: 10.1093/ajcp/aqab202. Am J Clin Pathol. 2022. PMID: 34875001
This study was designed to identify the tumors that most frequently metastasize to the stomach and the morphologic features that can provide clues to investigate the possibility of metastasis and predict the primary sites. METHODS: All patients with metastatic …
This study was designed to identify the tumors that most frequently metastasize to the stomach and the morphologic features that can …
Role of Somatostatin Signalling in Neuroendocrine Tumours.
Rogoza O, Megnis K, Kudrjavceva M, Gerina-Berzina A, Rovite V. Rogoza O, et al. Int J Mol Sci. 2022 Jan 27;23(3):1447. doi: 10.3390/ijms23031447. Int J Mol Sci. 2022. PMID: 35163374 Free PMC article. Review.
Somatostatin (SST) is a small peptide that exerts inhibitory effects on a wide range of neuroendocrine cells. Due to the fact that somatostatin regulates cell growth and hormone secretion, somatostatin receptors (SSTRs) have become valuable targets for the treatment of dif …
Somatostatin (SST) is a small peptide that exerts inhibitory effects on a wide range of neuroendocrine cells. Due to the fact that so …
Immunotherapy and potential predictive biomarkers in the treatment of neuroendocrine neoplasia.
Xu G, Wang Y, Zhang H, She X, Yang J. Xu G, et al. Future Oncol. 2021 Mar;17(9):1069-1081. doi: 10.2217/fon-2020-0703. Epub 2020 Nov 2. Future Oncol. 2021. PMID: 33136448 Review.
Neuroendocrine neoplasias (NENs) are a heterogeneous group of rare tumors scattered throughout the body. ...Immunotherapy has provided new treatment approaches for many cancer types, including neuroendocrine tumors, but predictive biomarkers of …
Neuroendocrine neoplasias (NENs) are a heterogeneous group of rare tumors scattered throughout the body. ...Immunotherapy has …
The role of resection for melanoma metastases to the pancreas.
Guerra F, Coletta D, Deutsch GB, Giuliani G, Patriti A, Fischer TD, Coratti A; Collaborators. Guerra F, et al. HPB (Oxford). 2022 Dec;24(12):2045-2052. doi: 10.1016/j.hpb.2022.08.012. Epub 2022 Sep 5. HPB (Oxford). 2022. PMID: 36167766 Free article. Review.
BACKGROUND: Among patients with distant metastatic melanoma, the site of metastases is the most significant predictor of survival and visceral-nonpulmonary metastases hold the highest risk of poor outcomes. ...Incomplete resection and concomitant extrapancreatic met …
BACKGROUND: Among patients with distant metastatic melanoma, the site of metastases is the most significant predictor of survi …
313 results